Skip to main content

Table 1 Baseline clinical characteristics of the study population

From: Left atrial volume predicts adverse cardiac and cerebrovascular events in patients with hypertrophic cardiomyopathy

 

Total

Group A

Group B

P-value

Age

61 ± 13

64 ± 12

59 ± 12

0.14

Male

73 (72%)

18 (74%)

55 (71%)

0.63

BPs (mmHg)

130 ± 19

137 ± 23

128 ± 17

0.04

BPd (mmHg)

77 ± 10

79 ± 10

76 ± 10

0.14

Height (m)

1.62 ± 0.09

1.60 ± 0.08

1.63 ± 0.09

0.12

Weight (kg)

61.8 ± 11.1

61.9 ± 9.6

61.7 ± 11.8

0.94

BSA (m2 )

1.67 ± 0.18

1.65 ± 0.16

1.67 ± 0.19

0.75

History of

HT

43 (42%)

16 (67%)

27 (35%)

<0.0001

DM

10 (10%)

3 (13%)

7 (9%)

0.37

HL

49 (48%)

12 (50%)

37 (47%)

0.67

PAF

23 (23%)

13 (54%)

10 (13%)

<0.0001

Medications

Aspirin

15 (15%)

8 (33%)

7 (9%)

<0.0001

Warfarin

4 (17%)

4 (17%)

0

<0.001

Calcium ant.

41 (40%)

11 (46%)

30 (38%)

0.25

Beta-blockers

44 (43%)

11 (46%)

33 (42%)

0.57

Diuretics

6 (6%)

3 (13%)

3 (4%)

0.02

ACE inhibitor

19 (19%)

8 (33%)

11 (14%)

0.002

  1. BPs, systolic blood pressure; BPd, diastolic blood pressure
  2. BSA, body surface area; PAF, paroxysmal atrial fibrillation